Project Grant R43DA051296

This Project Grant awarded by the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop novel small molecule therapeutics for the safe and effective treatment of Opioid Use Disorder (OUD). The $399,414 award will fund the development of an AI-powered drug discovery platform called M3.AI, which will integrate target-based and phenotype-based methodologies to identify new polypharmacological lead compounds. The platform will...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $398,137 to Boston Interactome LLC to develop high-precision epigenetic therapeutics for opioid use disorder (OUD). The project aims to identify small-molecule compounds that can disrupt specific protein-protein interactions in epigenetic complexes, such as the G9A complex, to regulate gene expression and mitigate the effects of chronic...

This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is supporting the development of a novel intranasal formulation of a derivative of naloxone to reverse opioid-induced respiratory depression (OIRD) caused by high-potency opioids such as fentanyl. The $1,539,426 award to Serodopa Therapeutics Inc., spanning September 2024 to August 2026, aims to complete the formulation development and preclinical testing...

The National Institute on Drug Abuse (NIDA), part of the U.S. Department of Health and Human Services, awarded a $267,000 Project Grant (CFDA 93.279 - Drug Use and Addiction Research Programs) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to develop "depot formulations" - injectable, subcutaneous drug delivery systems - for opioid painkillers. The goal is to create tamper-resistant and diversion-proof opioid formulations that can provide...

The University of Pittsburgh - Of The Commonwealth System of Higher Education was awarded a $2,828,679 Project Grant from the National Institute of Dental and Craniofacial Research (CFDA 93.121 - Oral Diseases and Disorders Research) to investigate overcoming immunotherapy resistance in head and neck cancer through the use of opioid antagonists. The research will utilize preclinical mouse models to study the impact of opioid-mediated immune suppression on anti-tumor immunity and the potential of...

The $858,600 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex as potential targets for developing novel treatments for opioid use disorder (OUD). The research aims to take an unbiased transcriptomics approach to identify GPCR transcripts in these...

This $11,811,988 Cooperative Agreement award from the National Institute on Drug Abuse (NIDA), under the CFDA 93.279 Drug Use and Addiction Research Programs, supports the development of the novel mu-opioid receptor antagonist methocinnamox (MCAM) for preventing opioid relapse and overdose. The award to the University of Texas Health Science Center at San Antonio aims to: 1) submit an Investigational New Drug (IND) application for MCAM, 2) complete Phase 1 and 1b clinical trials, 3) plan a Phase...

This Cooperative Agreement awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) provides $11,872,077 in funding to Sparian Biosciences Inc. (doing business as Palion Therapeutics) for the development of SBS-226, a novel chemical entity targeting the mu-opioid receptor (MOR) and delta-opioid receptor (DOR) for the treatment of opioid use disorder (OUD). The project involves comprehensive IND-enabling development and a Phase 1...

This $1,717,104 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund a 3-year community-engaged effort to adapt, produce, and pilot test a written "Youth Overdose Prevention Toolkit" for use by clinicians in pediatric healthcare settings. The toolkit will provide practical, developmentally appropriate guidance on delivering evidence-based interventions including naloxone, drug testing strips,...

This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,902,673.00 to Rutgers, The State University of New Jersey to establish the OPRM1 exon 7-associated variants as novel therapeutic targets for mitigating adverse effects of clinically used mu opioids without altering analgesia in pain management. The award period runs from September 30, 2024 to May 31, 2029. The key products and services...